135 results on '"Drandi D"'
Search Results
2. Minimal Residual Disease Analysis by Monitoring Immunoglobulin and T-Cell Receptor Gene Rearrangements by Quantitative PCR and Droplet Digital PCR
3. Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma
4. P1245: CLINICAL IMPACT OF IMMUNOGLOBULIN HEAVY CHAIN REPERTOIRE IN MANTLE CELL LYMPHOMA: A STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III MCL0208 TRIAL.
5. P1256: A NOVEL DROP-OFF DIGITAL PCR ASSAY FOR CXCR4 MUTATION SCREENING IN IGM GAMMOPATHIES: FIRST DATA FROM THE FONDAZIONE ITALIANA LINFOMI BIO-WM STUDY
6. Minimal Residual Disease Analysis by Monitoring Immunoglobulin and T-Cell Receptor Gene Rearrangements by Quantitative PCR and Droplet Digital PCR
7. Quality of facility-based maternal and newborn care around the time of childbirth during the COVID-19 pandemic: online survey investigating maternal perspectives in 12 countries of the WHO European Region
8. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival
9. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
10. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells
11. Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia
12. Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients
13. MINIMAL RESIDUAL DISEASE (MRD) EVALUATION IN LYMPHOMAS WITHIN THE FIL (FONDAZIONE ITALIANA LINFOMI) MRD NETWORK: INTER-LABORATORY REPRODUCIBILITY ON BORDERLINE SAMPLES
14. PS1312 QPCR, MFC AND DDPCR: COMPARISON ON MRD SAMPLES FROM THREE PROSPECTIVE TRIALS OF THE EUROPEAN MCL NETWORK
15. PS1319 MYD88L265P MUTATION IN WM AND IGM-MGUS: COMPARISON OF FEASIBILITY AND BENEFIT BETWEEN DDPCR AND STANDARD ASQPCR IN CD19+ SELECTED AND UNSELECTED SAMPLES
16. FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY
17. A Novel Digital PCR Assay for MYD88 L265P Mutation Detection in Waldenstrom Macroglobulinemia: Minimal Residual Disease Monitoring and Characterization on Circulating Free DNA
18. NOVEL MOLECULAR MARKERS FOR MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN MANTLE CELL AND FOLLICULAR LYMPHOMA: THE TARGETED LOCUS AMPLIFICATION (TLA) NGS STRATEGY
19. HIGH RATES OF PROLONGED MOLECULAR REMISSIONS AFTER TANDEM AUTOLOGOUS-NONMYELOABLATIVE ALLOGRAFTING IN NEWLY DIAGNOSED MYELOMA
20. Ficoll‐hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis.
21. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia
22. Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma
23. Expression of Met Mrna As Prognostic Marker In Multiple Myeloma Patients Treated With Novel Drugs
24. Post Transplant Consolidation With Bortezomib, Thalidomide and Dexamethasone Induces A Clinically Significant Shrinkage of Residual Tumor Burden Measured By Real Time Pcr
25. Early Consolidation With Bortezomib, Thalidomide and Dexamethasone In Mm Patients In Cr Or Vgpr Following Autologous Transplantation Induces Molecular Remissions
26. Clinical and molecular results of a post-transplant consolidation with Bortezomib, Thalidomide and Dexamethasone in Multiple Myeloma
27. Impact of consolidation with bortezomib, thalidomide and dexamethasone on residual multiple myeloma cells after autologous transplantation assessed by qualitative and quantitative PCR
28. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival
29. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
30. Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests
31. REAL TIME PCR IN MULTIPLE MYELOMA: QUANTITATIVE ANALYSIS OF TUMOR CONTAMINATION OF STEM CELL HARVESTS
32. Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes
33. Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes
34. 2.28 Identification by Serological Proteome Analysis (SERPA) of Novel Tumor Associated Antigens in Chronic Lymphocytic Leukemia (CLL)
35. 2.37 Accelerated Activity of the Mevalonate Pathway Supports the Immune Escape and Multidrug- Resistance Phenotype of IGHV Unmutated Chronic Lymphocytic Leukemia Cells
36. Report of Consensus Panel 3 from the 11thInternational Workshop on Waldenström's Macroglobulinemia: Recommendations for Molecular Diagnosis in Waldenström's Macroglobulinemia
37. A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients
38. EXTRACELLULAR VESICLES AS POTENTIAL BIOMARKER FOR ACUTE GVHD
39. THE METABOLISM OF MEVALONATE AS A SIGNALING PATHWAY INFLUENCING TUMOR-HOST INTERACTIONS AND DISEASE PROGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
40. SHORT TELOMERE LENGTH IS AN INDEPENDENT PREDICTOR OF SURVIVAL, PROGRESSION, RICHTER'S SYNDROME TRANSFORMATION AND RECURRENT INFECTIONS: AN ANALYSIS ON 421 CLL PATIENTS INCLUDING BLINDED VALIDATION ON 230 CASES
41. Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network
42. Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network
43. Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis
44. Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial.
45. Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
46. The gray area of RQ-PCR-based measurable residual disease: subdividing the "positive, below quantitative range" category.
47. Editorial: The emerging role of liquid biopsies in hematologic disorders.
48. Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines.
49. Molecular remission is an independent predictor of progression-free survival in patients with Waldenström macroglobulinemia treated with chemo-immunotherapy: Results from the FIL_BIOWM study.
50. Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.